SEC Form 4/A · accession 0001062993-17-000505
BIOSPECIFICS TECHNOLOGIES CORP · BSTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Thomas Wegman
Officer — President · Director · 10% Owner
Period of report
Nov 28, 2016
Accepted (ET)
Feb 3, 2017 · 6:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875622
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.001 par valueF1 | Nov 28, 2016 | S | 11,055 | $48.0369 | D | 301,494 | D | |
| Common Stock, $.001 par valueF2,F3 | Nov 29, 2016 | S | 8,945 | $48.3161 | D | 292,549 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The selling price of $48.0369 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $47.50 to $49.40. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2The selling price of $48.3161 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $48.25 to $48.77. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The purpose of this Form 4/A is solely to correct the amount of securities beneficially owned by the reporting person and does not represent any acquisition or disposition of shares by the reporting person.